Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.
Ghassan K. Abou-Alfa, MD, from the Memorial Sloan Kettering Cancer Center, discusses the current role for ramucirumab (Cyramza) for the treatment of patients with hepatocellular carcinoma (HCC) in the second-line setting.
In May 2019, theFDA granted approval to ramucirumab monotherapy for the treatment of patients with HCC who have an alpha-fetoprotein (AFP) level of ≥400 ng/mLand have been previously treated with sorafenib (Nexavar), based on data from the phase III REACH-2 trial. For now, this agent is only applicable to patients with an elevated AFP above 400, says Abou-Alfa, but elevated AFP levels remain a complex piece of information.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More